Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…Abstract Number: 1806 • ACR Convergence 2024
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by production of auto-antibodies, immune complex formation and an activated type I interferon system. Both genetic and environmental…Abstract Number: 1945 • ACR Convergence 2024
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates
Background/Purpose: The transition period from pediatric to adult-oriented rheumatology care is a high-risk time for disease flare and poor outcomes. We previously demonstrated implementation of…Abstract Number: 2371 • ACR Convergence 2024
The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
Background/Purpose: Recently, a gain of-function mutation within TLR7 was identified to induce SLE in a murine model and increased the survival of activated B lymphocytes,…Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…Abstract Number: 2408 • ACR Convergence 2024
Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Our prior qualitative work discovered a subgroup of patients with SLE who experience persistent symptoms of fatigue and widespread pain, even on self-described “good…Abstract Number: 2424 • ACR Convergence 2024
Anifrolumab Effects on Response to Influenza Vaccine in SLE
Background/Purpose: Risk for infections in systemic lupus may arise from immunosuppressant treatments or intrinsic immune defects. Disordered interferon signals are a hallmark of SLE. Anifrolumab, which…Abstract Number: 2545 • ACR Convergence 2024
Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most severe organ manifestations in SLE and is associated with poor quality of life. We…Abstract Number: 2604 • ACR Convergence 2024
Altered Expression of Ecto-5′-Nucleotidase (NT5E) in SLE Patients Based on Disease-associated Genotype
Background/Purpose: The NT5E gene, encoding Ecto-5'-Nucleotidase/CD73, is expressed on the surface of immune system cells and is critical for converting AMP/IMP to adenosine/inosine, important immunosuppressive purine nucleosides.…Abstract Number: PP15 • ACR Convergence 2024
Breathing Mindfully and How to Control Anxiety in Lupus Patients
Background/Purpose: For over four decades, Systemic Lupus Erythematosus has impacted my Quality of Life.. I was diagnosed in 1983- my entire life was changed. I…Abstract Number: 0092 • ACR Convergence 2024
A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…Abstract Number: 0167 • ACR Convergence 2024
Epidemiology of Falls in a Diverse Cohort of Adults with SLE
Background/Purpose: While often preventable, falls are a common, costly, and serious outcome in the U.S. population: more than one in four adults ³65 years old…Abstract Number: 0191 • ACR Convergence 2024
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune rheumatic disease whose prognosis varies by race and sex. To understand whether the cognitive processes of…Abstract Number: 0353 • ACR Convergence 2024
Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…Abstract Number: 0442 • ACR Convergence 2024
Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) affects women of childbearing years and confers an increased risk of pregnancy complications. Risk of adverse events in pregnancy is…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 150
- Next Page »